Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDLNASDAQ:OCGNNASDAQ:OCSNASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$8.03-1.5%$7.99$6.38▼$19.09$775.93M1.521.22 million shs1.10 million shsOCGNOcugen$0.68+4.0%$0.64$0.52▼$2.06$198.39M3.784.80 million shs3.49 million shsOCSOculis$18.27+1.4%$18.82$10.79▼$23.08$797.71M0.1946,619 shs25,926 shsVIRVir Biotechnology$5.50+1.3%$7.26$4.95▼$14.45$754.29M1.141.34 million shs713,272 shs20 Stocks to Sell NowGet This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals0.00%+4.56%-8.44%+3.61%-55.36%OCGNOcugen0.00%-1.59%+23.77%-4.31%-52.82%OCSOculis0.00%+9.07%-2.51%-19.66%+53.53%VIRVir Biotechnology0.00%-0.54%-20.86%-45.60%-33.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals2.4705 of 5 stars3.51.00.00.02.73.30.6OCGNOcugen1.2928 of 5 stars3.51.00.00.02.60.00.0OCSOculis2.0437 of 5 stars3.53.00.00.02.40.00.6VIRVir Biotechnology2.5104 of 5 stars3.41.00.00.01.83.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 3.00Buy$19.88147.51% UpsideOCGNOcugen 3.00Buy$6.33832.20% UpsideOCSOculis 3.00Buy$30.2565.57% UpsideVIRVir Biotechnology 2.86Moderate Buy$33.57510.39% UpsideCurrent Analyst Ratings BreakdownLatest OCGN, VIR, OCS, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $32.004/17/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.004/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.004/9/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.003/13/2025OCSOculisRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$37.00 ➝ $41.003/13/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/13/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $29.003/6/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/6/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/4/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.003/3/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 4/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$169.12M4.59N/AN/A$0.98 per share8.19OCGNOcugen$4.06M48.93N/AN/A$0.16 per share4.25OCSOculis$980K813.98N/AN/A$2.87 per share6.37VIRVir Biotechnology$63.71M11.84N/AN/A$11.82 per share0.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$160.28M-$0.52N/A133.83N/A-52.53%-93.34%-44.77%5/6/2025 (Estimated)OCGNOcugen-$63.08M-$0.19N/AN/AN/A-532.51%-154.75%-90.79%5/13/2025 (Estimated)OCSOculis-$98.92M-$2.31N/AN/AN/A-8,043.28%-71.31%-56.85%5/14/2025 (Estimated)VIRVir Biotechnology-$615.06M-$3.82N/AN/AN/A-678.40%-36.71%-31.00%5/1/2025 (Estimated)Latest OCGN, VIR, OCS, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.06N/AN/AN/A$50.57 millionN/A5/14/2025Q1 2025OCSOculis-$0.50N/AN/AN/AN/AN/A5/13/2025Q1 2025OCGNOcugen-$0.06N/AN/AN/AN/AN/A5/1/2025Q1 2025VIRVir Biotechnology-$0.83N/AN/AN/A$8.59 millionN/A3/11/2025Q4 2024OCSOculis-$0.48-$0.76-$0.28-$0.76$0.21 millionN/A3/5/2025Q4 2024OCGNOcugen-$0.05-$0.05N/A-$0.05$0.30 million$0.76 million2/26/2025Q4 2024VIRVir Biotechnology-$0.85-$0.76+$0.09-$0.76$8.14 million$12.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.972.60OCGNOcugen0.042.582.58OCSOculis0.014.024.02VIRVir BiotechnologyN/A8.948.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%OCGNOcugen10.27%OCSOculis22.30%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals4.80%OCGNOcugen4.29%OCSOculisN/AVIRVir Biotechnology15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7096.63 million91.74 millionOptionableOCGNOcugen80292.01 million278.82 millionOptionableOCSOculis243.66 millionN/ANot OptionableVIRVir Biotechnology580137.14 million116.24 millionOptionableOCGN, VIR, OCS, and AVDL HeadlinesRecent News About These CompaniesQuinn Opportunity Partners LLC Purchases Shares of 65,976 Vir Biotechnology, Inc. (NASDAQ:VIR)April 14, 2025 | marketbeat.comNew Mpro inhibitors revealed in Vir Biotechnology patentApril 11, 2025 | bioworld.comExodusPoint Capital Management LP Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)April 11, 2025 | marketbeat.comVir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Here's WhyApril 9, 2025 | marketbeat.comADAR1 Capital Management LLC Sells 255,118 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)April 9, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells $474,286.40 in StockApril 6, 2025 | marketbeat.comPrudential Financial Inc. Sells 180,800 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)April 6, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Here's What HappenedApril 2, 2025 | marketbeat.comStock Movers: Moderna, Tesla, Canada GooseMarch 31, 2025 | bloomberg.comWINTON GROUP Ltd Sells 38,730 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)March 31, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from AnalystsMarch 30, 2025 | marketbeat.comArtisan Partners Limited Partnership Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)March 30, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the companyMarch 28, 2025 | finance.yahoo.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Time to Sell?March 27, 2025 | marketbeat.com49,651 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Fox Run Management L.L.C.March 27, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Holdings Raised by Charles Schwab Investment Management Inc.March 23, 2025 | marketbeat.comBrii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial ResultsMarch 21, 2025 | prnewswire.com51,967 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Tejara Capital LtdMarch 19, 2025 | marketbeat.comBank of New York Mellon Corp Lowers Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)March 19, 2025 | marketbeat.comVir enrols first subject in Phase III programme to assess CHD therapyMarch 14, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Can SoundHound AI Double? What the Fundamentals and Deals RevealBy Gabriel Osorio-Mazilli | March 25, 2025View Can SoundHound AI Double? What the Fundamentals and Deals RevealCrowdStrike Stock is a Buy as Cyberthreat Environment ExpandsBy Chris Markoch | April 15, 2025View CrowdStrike Stock is a Buy as Cyberthreat Environment Expands3 Energy Stock Winners Even as Oil Prices PlungeBy Chris Markoch | April 11, 2025View 3 Energy Stock Winners Even as Oil Prices PlungeCoca-Cola Stock Looks Refreshing After the Relief Rally By Chris Markoch | April 13, 2025View Coca-Cola Stock Looks Refreshing After the Relief Rally OCGN, VIR, OCS, and AVDL Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$8.03 -0.12 (-1.47%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$8.16 +0.13 (+1.67%) As of 04/17/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Ocugen NASDAQ:OCGN$0.68 +0.03 (+4.01%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.67 -0.01 (-0.79%) As of 04/17/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.Oculis NASDAQ:OCS$18.27 +0.25 (+1.39%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$18.27 0.00 (0.00%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Vir Biotechnology NASDAQ:VIR$5.50 +0.07 (+1.29%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.50 0.00 (0.00%) As of 04/17/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
